Literature DB >> 25933618

Overexpression of cutaneous mitochondrial superoxide dismutase in recent-onset type 2 diabetes.

Dan Ziegler1, Alexander Strom, Jutta Brüggemann, Iris Ziegler, Bernd Ringel, Sonja Püttgen, Michael Roden.   

Abstract

AIMS/HYPOTHESIS: Oxidative stress and microvascular damage have been implicated in the pathogenesis of diabetic neuropathy, with manganese superoxide dismutase 2 (SOD2) responsible for superoxide detoxification in mitochondria. We hypothesised that patients with recently diagnosed type 2 diabetes would show an altered cutaneous expression of SOD2 and endothelial cell area.
METHODS: In this cross-sectional study, we assessed skin biopsies using immunohistochemistry, peripheral nerve function and heart rate variability in 69 participants of the German Diabetes Study with recently diagnosed type 2 diabetes and 51 control individuals.
RESULTS: Subepidermal SOD2 area in the distal leg was increased by ~60% in the diabetic group vs the controls (0.24 ± 0.02% vs 0.15 ± 0.02%; p = 0.0005) and was correlated with an increasing duration of diabetes (r = 0.271; p = 0.024) and with the low frequency/high frequency ratio (β = 0.381; p = 0.002) as an indicator of sympathovagal balance. The area of the subepidermal endothelial cells (measured by CD31 staining) did not differ between the groups. CONCLUSIONS/
INTERPRETATION: Cutaneous antioxidative defence is enhanced in relation to the duration of diabetes and is linked to a cardiac sympathovagal imbalance towards a sympathetic predominance in individuals with recently diagnosed type 2 diabetes without evidence of endothelial cell damage. Whether cutaneous SOD2 levels can predict the development of diabetic neuropathy remains to be determined in prospective studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25933618     DOI: 10.1007/s00125-015-3609-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

1.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.

Authors:  T Nishikawa; D Edelstein; X L Du; S Yamagishi; T Matsumura; Y Kaneda; M A Yorek; D Beebe; P J Oates; H P Hammes; I Giardino; M Brownlee
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

2.  Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes.

Authors:  D Manzella; M Barbieri; E Ragno; G Paolisso
Journal:  Am J Clin Nutr       Date:  2001-06       Impact factor: 7.045

Review 3.  Reactive oxygen species and autonomic regulation of cardiac excitability.

Authors:  Edward J F Danson; David J Paterson
Journal:  J Cardiovasc Electrophysiol       Date:  2006-05

Review 4.  Efficacy of α-lipoic acid in diabetic neuropathy.

Authors:  Nikolaos Papanas; Dan Ziegler
Journal:  Expert Opin Pharmacother       Date:  2014-11-10       Impact factor: 3.889

Review 5.  Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity.

Authors:  Peter J Dyck; James W Albers; Henning Andersen; Joseph C Arezzo; Geert-Jan Biessels; Vera Bril; Eva L Feldman; William J Litchy; Peter C O'Brien; James W Russell
Journal:  Diabetes Metab Res Rev       Date:  2011-10       Impact factor: 4.876

Review 6.  Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression.

Authors:  Igor N Zelko; Thomas J Mariani; Rodney J Folz
Journal:  Free Radic Biol Med       Date:  2002-08-01       Impact factor: 7.376

7.  Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes.

Authors:  Dan Ziegler; Nikolaos Papanas; Andrey Zhivov; Stephan Allgeier; Karsten Winter; Iris Ziegler; Jutta Brüggemann; Alexander Strom; Sabine Peschel; Bernd Köhler; Oliver Stachs; Rudolf F Guthoff; Michael Roden
Journal:  Diabetes       Date:  2014-02-26       Impact factor: 9.461

8.  SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy.

Authors:  Andrea M Vincent; James W Russell; Kelli A Sullivan; Carey Backus; John M Hayes; Lisa L McLean; Eva L Feldman
Journal:  Exp Neurol       Date:  2007-08-03       Impact factor: 5.330

Review 9.  Brain stem oxidative stress and its associated signaling in the regulation of sympathetic vasomotor tone.

Authors:  Samuel H H Chan; Julie Y H Chan
Journal:  J Appl Physiol (1985)       Date:  2012-07-26

10.  Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy.

Authors:  Cristian Quattrini; Maria Jeziorska; Andrew J M Boulton; Rayaz A Malik
Journal:  Diabetes Care       Date:  2007-10-12       Impact factor: 19.112

  10 in total
  4 in total

Review 1.  Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015.

Authors:  Nikolaos Papanas; Dan Ziegler
Journal:  Rev Diabet Stud       Date:  2015-08-10

2.  Cohort profile: the German Diabetes Study (GDS).

Authors:  Julia Szendroedi; Aaruni Saxena; Katharina S Weber; Klaus Strassburger; Christian Herder; Volker Burkart; Bettina Nowotny; Andrea Icks; Oliver Kuss; Dan Ziegler; Hadi Al-Hasani; Karsten Müssig; Michael Roden
Journal:  Cardiovasc Diabetol       Date:  2016-04-07       Impact factor: 9.951

3.  Lower serum extracellular superoxide dismutase levels are associated with polyneuropathy in recent-onset diabetes.

Authors:  Alexander Strom; Kirti Kaul; Jutta Brüggemann; Iris Ziegler; Ilka Rokitta; Sonja Püttgen; Julia Szendroedi; Karsten Müssig; Michael Roden; Dan Ziegler
Journal:  Exp Mol Med       Date:  2017-11-17       Impact factor: 8.718

4.  BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy.

Authors:  Gidon J Bönhof; Gundega Sipola; Alexander Strom; Christian Herder; Klaus Strassburger; Birgit Knebel; Claudia Reule; Jan-Christoph Wollmann; Andrea Icks; Hadi Al-Hasani; Michael Roden; Oliver Kuss; Dan Ziegler
Journal:  BMJ Open       Date:  2022-02-03       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.